[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ATE203415T1 - Orales verabreichungssystem von chemischmodifizierten proteinen g-csf - Google Patents

Orales verabreichungssystem von chemischmodifizierten proteinen g-csf

Info

Publication number
ATE203415T1
ATE203415T1 AT95911690T AT95911690T ATE203415T1 AT E203415 T1 ATE203415 T1 AT E203415T1 AT 95911690 T AT95911690 T AT 95911690T AT 95911690 T AT95911690 T AT 95911690T AT E203415 T1 ATE203415 T1 AT E203415T1
Authority
AT
Austria
Prior art keywords
chemically modified
csf
oral administration
modified proteins
administration system
Prior art date
Application number
AT95911690T
Other languages
English (en)
Inventor
Alan D Habberfield
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of ATE203415T1 publication Critical patent/ATE203415T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AT95911690T 1994-02-08 1995-02-08 Orales verabreichungssystem von chemischmodifizierten proteinen g-csf ATE203415T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19418794A 1994-02-08 1994-02-08
US37912195A 1995-02-01 1995-02-01
PCT/US1995/001752 WO1995021629A1 (en) 1994-02-08 1995-02-08 Oral delivery of chemically modified proteins

Publications (1)

Publication Number Publication Date
ATE203415T1 true ATE203415T1 (de) 2001-08-15

Family

ID=26889779

Family Applications (2)

Application Number Title Priority Date Filing Date
AT95911690T ATE203415T1 (de) 1994-02-08 1995-02-08 Orales verabreichungssystem von chemischmodifizierten proteinen g-csf
AT00122148T ATE311908T1 (de) 1994-02-08 1995-02-08 Orale verabreichung von chemisch modifizierten proteinen

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT00122148T ATE311908T1 (de) 1994-02-08 1995-02-08 Orale verabreichung von chemisch modifizierten proteinen

Country Status (12)

Country Link
US (2) US20020099001A1 (de)
EP (2) EP0726778B1 (de)
AT (2) ATE203415T1 (de)
AU (1) AU1916295A (de)
DE (2) DE69534676T2 (de)
DK (2) DK0726778T3 (de)
ES (2) ES2159630T3 (de)
GR (1) GR3036625T3 (de)
HK (1) HK1036214A1 (de)
IL (1) IL112583A0 (de)
PT (1) PT726778E (de)
WO (1) WO1995021629A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5885567A (en) * 1993-10-22 1999-03-23 University Of Connecticut Treatment of infection in fowl by oral administration of avian interferon proteins
US6429290B1 (en) 1994-08-17 2002-08-06 The Rockefeller University OB polypeptides, modified forms and derivatives
US6350730B1 (en) 1994-08-17 2002-02-26 The Rockefeller University OB polypeptides and modified forms as modulators of body weight
US6471956B1 (en) 1994-08-17 2002-10-29 The Rockefeller University Ob polypeptides, modified forms and compositions thereto
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
TW517067B (en) * 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
US6013253A (en) * 1997-08-15 2000-01-11 Amgen, Inc. Treatment of multiple sclerosis using consensus interferon and IL-1 receptor antagonist
ES2447772T3 (es) 1998-10-16 2014-03-12 Biogen Idec Ma Inc. Conjugados de polialquilenglicol de interferón beta-1a y sus usos
JP4761621B2 (ja) 1998-10-16 2011-08-31 バイオジェン・アイデック・エムエイ・インコーポレイテッド インターフェロン−β融合タンパク質および使用
JO2291B1 (en) 1999-07-02 2005-09-12 اف . هوفمان لاروش ايه جي Erythropoietin derivatives
US6831158B2 (en) 2000-01-10 2004-12-14 Maxygen Holdings Ltd. G-CSF conjugates
US6646110B2 (en) 2000-01-10 2003-11-11 Maxygen Holdings Ltd. G-CSF polypeptides and conjugates
US6555660B2 (en) 2000-01-10 2003-04-29 Maxygen Holdings Ltd. G-CSF conjugates
AR027509A1 (es) 2000-01-10 2003-04-02 Maxygen Aps Conjugados g-csf
US20070167359A1 (en) * 2003-04-15 2007-07-19 Moshe Baru Pharmaceutical composition comprising proteins and/or polypeptides and colloidal particles
US7834147B2 (en) 2003-04-28 2010-11-16 Childrens Hospital Medical Center Saposin C-DOPS: a novel anti-tumor agent
US7943179B2 (en) * 2003-09-23 2011-05-17 Massachusetts Institute Of Technology pH triggerable polymeric particles
US7220407B2 (en) 2003-10-27 2007-05-22 Amgen Inc. G-CSF therapy as an adjunct to reperfusion therapy in the treatment of acute myocardial infarction
CA2586365A1 (en) 2004-11-05 2006-05-26 Northwestern University Use of scf and g-csf in the treatment of cerebral ischemia and neurological disorders
WO2006074467A2 (en) 2005-01-10 2006-07-13 Neose Technologies, Inc. Glycopegylated granulocyte colony stimulating factor
DE602006020562D1 (de) 2005-06-01 2011-04-21 Maxygen Inc Hren dafür
KR100694994B1 (ko) 2005-06-13 2007-03-14 씨제이 주식회사 사람 과립구 콜로니 형성인자 동종체
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
NZ583276A (en) 2007-08-27 2012-06-29 Biogenerix Ag Liquid formulations of granulocyte colony stimulating factor and polymer conjugates
WO2012018628A1 (en) 2010-07-26 2012-02-09 Board Of Regents, The University Of Texas System Methods for inducing an immune response via buccal and/or sublingual administration of a vaccine
US9974850B2 (en) 2013-01-25 2018-05-22 Board Of Regents, The University Of Texas System Immunogenic compositions and uses thereof
US20190298836A1 (en) * 2016-11-02 2019-10-03 Board Of Regents, The University Of Texas System Dissolvable films and methods of their use

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2792862B2 (ja) * 1988-07-30 1998-09-03 寛治 高田 経口腸溶製剤
DE68925966T2 (de) * 1988-12-22 1996-08-29 Kirin Amgen Inc Chemisch modifizierte granulocytenkolonie erregender faktor
US5342940A (en) * 1989-05-27 1994-08-30 Sumitomo Pharmaceuticals Company, Limited Polyethylene glycol derivatives, process for preparing the same
EP0452179B1 (de) * 1990-03-28 1996-06-12 Nippon Oil And Fats Company, Limited Polymerkombiniertes Arzneimittel zur Magenbehandlung und Verfahren zu dessen Herstellung
IE912365A1 (en) * 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
US5372808A (en) * 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
US6565841B1 (en) * 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
ZA933926B (en) * 1992-06-17 1994-01-03 Amgen Inc Polyoxymethylene-oxyethylene copolymers in conjuction with blomolecules
FR2693907B1 (fr) * 1992-07-23 1994-09-02 Rhone Poulenc Rorer Sa Procédé d'administration de solutions de facteur de stimulation des colonies granulocytaires.
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods

Also Published As

Publication number Publication date
ATE311908T1 (de) 2005-12-15
EP1090645A2 (de) 2001-04-11
WO1995021629A1 (en) 1995-08-17
DE69521880D1 (de) 2001-08-30
GR3036625T3 (en) 2001-12-31
IL112583A0 (en) 1995-05-26
DE69534676D1 (de) 2006-01-12
AU1916295A (en) 1995-08-29
DK0726778T3 (da) 2001-09-24
DK1090645T3 (da) 2006-03-27
EP1090645A3 (de) 2002-02-27
DE69521880T2 (de) 2002-01-03
ES2159630T3 (es) 2001-10-16
EP0726778B1 (de) 2001-07-25
US20020099001A1 (en) 2002-07-25
ES2251924T3 (es) 2006-05-16
EP0726778A1 (de) 1996-08-21
PT726778E (pt) 2001-12-28
US20030185795A1 (en) 2003-10-02
EP1090645B1 (de) 2005-12-07
HK1036214A1 (en) 2001-12-28
DE69534676T2 (de) 2006-08-17

Similar Documents

Publication Publication Date Title
DE69521880D1 (de) Orales verabreichungssystem von chemischmodifizierten proteinen g-csf
DK0733067T3 (da) N-terminalt kemisk modificerede proteinpræparater og fremgangsmåder
DK642587A (da) Insulinpraeparat
IL109403A0 (en) Oral drug delivery compositions and methods
DK0644932T3 (da) Oprensede former af DNase
IL112667A (en) 6-substituted derivatives of mycophenolic acid their preparation and pharmaceutical compositions containing them
WO1996024370B1 (en) Pharmaceutical non inorganic saline solutions for endonasal administration of a calcitonin
ATE191719T1 (de) Analoge des calcitonin aus lachs, ihre herstellung und ihre verwendung als medizin und als analytische reagentien
DE3773295D1 (de) Homogene rekombinante immun-interferon-fragmente und diese enthaltende pharmazeutische zusammensetzungen.
DE69314586D1 (de) Arzneimittelzusammensetzung enthaltend TCF-II
OA07270A (fr) Dérivés N-(vinblastinoyl-23) d'acide aminés, leur préparation et leur application thérapeutique.
DE69327693D1 (de) Interferon-Alpha/Beta bindendes Protein, seine Herstellung und seine enthaltende pharmazeutische Zusammensetzungen
MY104088A (en) Peptide-drugs compositions containing (alpha)-aminoboroic acid derivatives.
AU609435B2 (en) Prevention of bovine respiratory disease complex in cattle by administration of interferon
RU97113248A (ru) Усовершенствованная лекарственная форма человеческого интерферона-свеча
IT8522989A0 (it) Frazione ottenuta da listeria monocytogenes avente attivita'terapeutica, procedimento per lasua preparazione e composioni farmaceutiche che la contengono.
MX9604539A (es) Aminoacidos modificados para la distribucion de farmaco.
IT1238210B (it) Esteri del cefamandolo nafato, procedimento per la loro preparazione erelative composizioni farmaceutiche.
IT208775Z2 (it) Siringa per l'anestesia intraligamentosa.
IT1251496B (it) Derivati imidazotiadiazolici ad attivita' diuretica, procedimenti per la loro preparazione e composizioni che li contengono
FR2722500B1 (fr) Derives d'acide 2-thienylimidazo(1,2-a) benzimidazole-3-acetique, leur preparation et leur application en therapeutique
RU96104616A (ru) Пептид, обладающий влиянием на регенерацию кроветворной и иммунной систем, и фармацевтическая композиция на его основе
ZA879325B (en) Prevention of bovine respiratory disease complex in cattle by administration of interferon

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification